---
document_type: gtm_research_ledger
title: Measures Registry GTM Research Ledger
status: working_research_ledger
version: v1
timestamp: 2026-08-21
operator: op044
author: chazz
system: measures_registry
scope: go_to_market_research_and_market_validation
authoritative_custody: git
repository: c3codex/c3-Field
branch: gtm-ledger-v1
registry_standing: unregistered
source_authority_index: project_source_authority_index_v7.meta.md
source_concordance: source_concordance_current_v8.meta.md
operational_concordance: c3_operational_concordance_v3.meta.md
map_terminology_standing: held_unresolved
---

# Measures Registry GTM Research Ledger

## Purpose
Maintain a durable, evidence-led record of Measures Registry go-to-market research. Research evidence does not itself create Registry standing, publication authority, compliance claims, sales activation, or MAP terminology resolution.

## Governing Sequence
`MARKET → ICP → BUYER → OFFER → ACQUISITION`

Later evidence may move a hypothesis backward. A persuasive report is not passage evidence by itself.

## Five GTM Gates
| Gate | Decision | Governing question | Passage evidence |
| --- | --- | --- | --- |
| G1 Market | Select or reject a candidate market | Is there observable demand worth pursuing? | purchasing behavior, forcing events, accessibility, alternatives, ability to pay, counterevidence |
| G2 ICP | Define organizations most likely to buy | Which organizations exhibit conditions associated with demand? | organization type, AI deployment, governance maturity, trigger, ownership |
| G3 Buyer | Identify people who experience, own, fund, or block the work | Who feels the problem, owns it, approves spending, and influences procurement? | role evidence, interviews, procurement path, budget authority, blockers |
| G4 Offer | Define what the buyer will purchase | What bounded outcome, deliverable, price, and credibility package will the buyer accept? | buyer language, purchasing evidence, offer tests, price evidence, objections, conversion behavior |
| G5 Acquisition | Establish repeatable qualified demand | Can Measures Registry reliably reach and convert the buyer? | target cohort, channel response, assessment activity, conversations, opportunities, revenue |

## Research Record Schema
Preserve: `record_id`, `date`, `gate`, `candidate_market_or_segment`, `hypothesis`, `evidence`, `counterevidence`, `confidence`, `unresolved_gap`, `research_method`, `source`, `finding`, `decision_implication`, `standing`, `operator_disposition`.

Recommended standings: `candidate_under_validation`, `supported_pending_market_validation`, `supported`, `contradicted`, `held_for_evidence`, `rejected`, `operator_confirmed`.

## Case 001 — U.S. Healthcare Providers
### Case Standing
`candidate_under_validation`

Healthcare is the first candidate vertical. Measures Registry remains vertical-agnostic; healthcare is being tested as an initial beachhead, not adopted as company identity.

## Research Round 001 — Healthcare Market / ICP / Offer
Date: 2026-08-21
Standing: `research_findings_not_registry_registered`

### G1.1 — Demonstrated Healthcare AI-Governance Purchasing Behavior
**Finding:** `supported`

Provider-side AI-governance demand has moved beyond theoretical regulatory concern. Current research found direct evidence of formal procurement, outside advisory demand, governance-platform purchases, procurement gating, and governance affecting vendor selection.

Evidence set includes:
- Hawaii Health Systems Corporation RFP 25-005: external healthcare AI technology legal consulting, governance formation, education, procurement/contract guidance, and ongoing advisory across community-serving facilities. Public awardee and final contract value remain unverified.
- UT Health San Antonio RFP 745-26-P33: AI governance and monitoring platform plus associated services.
- Mercyhealth selection of Vitea: regional nonprofit provider purchasing external governance infrastructure after AI expanded across clinical and operational workflows.
- JPS Health Network: AI Governance Questionnaire incorporated into procurement review.
- Impact Advisors: external clinical-AI governance/readiness consulting work for a health-system client.
- Governance-driven vendor selection/rejection behavior at larger systems provides additional behavioral context.

**Limitation:** market frequency, penetration, and typical transaction values remain unresolved.

### G1.2 — Forcing Event Correction
**Prior hypothesis:** RUAIH readiness may be the primary provider-side forcing event.

**Revised finding:** `supported_but_narrowed`

RUAIH is a credible, timely accelerator but is not required to explain observed healthcare governance demand. A broader forcing condition is better supported:

> AI deployment becomes sufficiently distributed across clinical and operational environments that existing security, procurement, ownership, and technology controls no longer provide adequate visibility and governance.

RUAIH, procurement requirements, patient-safety/quality responsibilities, and regulation may accelerate recognition of that condition.

### G1.3 — Candidate Governance Maturity Lifecycle
**Finding:** `working_model_supported`

`Experimentation → Proliferation → Governance Recognition → Governance Formation → External Purchase → Sustained Governance`

Current hypothesis: Measures Registry's strongest commercial entry window is **Governance Recognition → Governance Formation**.

Too early: insufficient perceived pain or urgency.
Too late: mature internal governance infrastructure, established advisory relationships, or enterprise governance platforms may already satisfy the need.

Illustrative evidence roles:
- Tahoe Forest Health System: governance recognition / formation signal through formal AI-governance initiative and policy/process development.
- HHSC: governance formation plus external consulting procurement.
- Mercyhealth: external governance-platform purchase.
- WellSpan: high-maturity benchmark with substantial internal capability and strategic external AI partnerships.

### G2.1 — ICP Refinement
**Finding:** `working_hypothesis_strengthened`

Replace a primarily size-based ICP with a condition-based hypothesis:

> Multi-site healthcare provider with meaningful and growing AI deployment, emerging formal governance requirements, identifiable responsibility for AI oversight, and insufficient mature internal governance infrastructure.

Positive prospect signals:
- multiple AI use cases across clinical and/or operational workflows;
- multi-site or multi-state complexity;
- governance committee, policy, or formal review activity;
- evidence of governance recognition but incomplete governance formation;
- openness to outside partnerships;
- identifiable accountable executive(s);
- no mature dedicated AI-governance function/platform apparent.

Negative signal:
- sophisticated AI deployment combined with mature dedicated internal governance capability may reduce initial MR fit.

**Implication:** governance maturity may predict fit better than employee count alone.

### G3.1 — Buyer Hypothesis Split
**Finding:** `single_buyer_model_rejected_as_oversimplification`

Buyer ownership appears to vary with the intervention purchased.

**Governance infrastructure/control layer:** CIO, CDAO, digital/IT leadership currently appear prominent in named purchases.

**Readiness/environment assessment/governance formation:** CMIO/clinical informatics, Quality/Patient Safety, and Compliance remain candidate owners, but the economic buyer for an MR-specific engagement is not yet validated.

Research must distinguish clinical champion, governance/process owner, technical owner, economic approver, procurement gatekeeper, and executive sponsor rather than assigning one universal healthcare AI-governance buyer.

### G4.1 — Competitive Pricing Evidence
**Finding:** `competitive_pricing_supported; MR_willingness_to_pay_unvalidated`

Observed advertised market pricing currently spans approximately:
- free self-assessment / maturity tools;
- ~$1.5K lightweight readiness assessment;
- ~$4.5K–$12K boutique readiness work;
- ~$12K–$20K hospital/service-line assessment;
- ~$15K–$35K governance design;
- ~$20K–$50K+ implementation;
- higher enterprise/platform/advisory engagements.

These are competitive benchmarks, not verified MR willingness-to-pay evidence. No MR price change is authorized by this research.

### G4.2 — Commodity Assessment Warning
**Finding:** `supported`

Free and lightweight healthcare AI-governance maturity assessments already exist. Therefore Measures Registry should not assume differentiation from an AI inventory, maturity score, gap list, or generic readiness report alone.

Candidate distinction requiring validation:

> Measures Registry evaluates the operating environment computational systems inherit: system relationships, identity, ownership, authority, responsibility, evidence, review, and sustained governance conditions.

The paid continuation must derive value from observed/evidenced environmental work rather than merely a more elaborate self-reported questionnaire.

### G4.3 — Preliminary Competitive Position
**Finding:** `differentiation_hypothesis_pending_buyer_validation`

Current category map:
- Joint Commission / CHAI: standards, readiness expectations, guidance;
- governance platforms such as Vitea: discovery/control/visibility;
- AI management platforms such as Signal 1: intake, portfolio governance, monitoring, management;
- consultancies/law firms: framework, policy, readiness, implementation, advisory;
- internal teams/free playbooks: no-purchase substitutes;
- Measures Registry candidate position: upstream environmental assessment/diagnosis before selecting the governance intervention.

Candidate positioning hypothesis:

> Measures Registry establishes what governance environment actually exists before the organization decides which governance intervention it needs.

This position may be complementary to platforms, consultants, counsel, and certification preparation rather than substitutive.

### G4.4 — Central Demand Hold: Upstream Position ≠ Upstream Demand
**Finding:** `HELD_FOR_BUYER_EVIDENCE`

> Upstream positioning does not establish upstream demand. Measures Registry must demonstrate that target buyers recognize, seek, or can be reliably activated around the need to assess their operating environment before selecting a governance intervention.

Falsification condition:

> If healthcare buyers do not perceive meaningful value in independently establishing environmental conditions before selecting governance tools, frameworks, consultants, or certification work, the proposed upstream MR position is not commercially differentiated.

This is now the central G4 validation hold.

## Current Evidence Gaps
1. Typical regional/community provider transaction values for governance/readiness work.
2. Named advisory engagements and selected vendors beyond platform purchases.
3. What causes providers to choose outside help rather than internal governance formation.
4. The pre-purchase decision: how providers determine what governance intervention they need.
5. MR-specific economic buyer and budget path.
6. Whether an independent upstream diagnostic is recognized as valuable before a platform/framework/certification purchase.
7. Frequency of governance purchasing across the target provider population.
8. Procurement thresholds, insurance/credential requirements, and accessibility for a small specialist provider.

## Next Course of Research
### Priority 1 — Pre-Purchase Decision Archaeology
For named providers that purchased a governance platform, consultant, or formal governance program, reconstruct:

`trigger → perceived problem → current-state assessment (if any) → internal owner → alternatives considered → solution category selected → purchase path → outcome`

Key question:

> When the organization realized it needed to govern AI more formally, how did it determine what it actually needed?

Search specifically for evidence of uncertainty before purchase: unclear inventory, ownership, authority, workflow, policy consistency, evidence, monitoring need, vendor-review friction, or inability to choose an intervention.

### Priority 2 — Competitive/Substitute Analysis
Analyze serious alternatives at the buying moment, not generic AI-governance companies.

For each category preserve:
`buyer → trigger → promise → methodology → deliverables → price → duration → credibility → sales entrance → post-assessment path → advantage over MR → gap relative to MR`

Categories:
1. direct readiness/environment assessment competitors;
2. implementation/advisory firms;
3. governance/AI-management platforms;
4. law/compliance firms;
5. Joint Commission/CHAI/free institutional guidance;
6. internal governance committees / do-it-yourself / no purchase.

### Priority 3 — Buyer Interviews
Use Nashville healthcare access and accelerator introductions to test the upstream-demand hold directly.

Core prompt:

> When your organization realized it needed to govern AI more formally, how did you figure out what you actually needed?

Do not lead interviewees with the MR upstream thesis. Reconstruct recent behavior.

### Priority 4 — Ten-Account Maturity Cohort
Build ten evidence-qualified regional/community provider accounts distributed across the maturity lifecycle. Observe where outside spending first appears and what conditions precede it.

### Priority 5 — Offer Test Only After Priorities 1–4
Do not finalize healthcare paid-assessment positioning from competitor architecture alone. Use buyer evidence to determine whether MR should sell:
- an independent upstream environmental assessment;
- readiness tied to an already recognized forcing event;
- governance-formation work;
- or another bounded entrance buyers already seek.

## Human Validation Prompts
- What happened the last time your organization introduced an AI system?
- Who had to review it before use?
- When did AI governance become a formal issue rather than an informal concern?
- How did you determine what kind of governance capability you needed?
- Did you assess the current environment before selecting a tool, consultant, policy framework, or committee structure?
- What was unclear at that point?
- What did you handle internally versus purchase externally?
- Who approved outside spending and from what budget?
- What would make an independent assessment useful—or unnecessary?

## MAP Boundary Hold
The unresolved MAP terminology conflict remains held. This ledger does not resolve MAP terminology or establish a canonical GTM↔MAP relationship.

Standing: `HELD — MAP terminology and GTM↔MAP canonical relation unresolved`

## Custody / Mutation Boundary
Current custody is Git only. The ledger remains unregistered. Research accumulation does not authorize Registry mutation, public publication, sales activation, outreach enrollment, deployment, contact enrichment, MAP resolution, or pricing changes.
